ClinicalTrials.gg
CompletedNCT04772105Updated Jul 14, 2026

Study of Two Multiple Intravitreal Doses of BAT5906 for Safety and Efficacy in Patients With Diabetic Macular Edema

A Phase 1/2 interventional study of 2.5mg of BAT5906 and 4.0mg of BAT5906 in Diabetic Macular Edema, sponsored by Bio-Thera Solutions. Completed at 19 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Bio-Thera Solutions · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 72 studies in Macular Edema with a site in China — 18 open to participants now, 22 under way, 4 of them phase 3. Macular Edema · China.

Enrollment
47th of 65
60 · median 140
Started
2020
with 4 others
Phase 1/2
7 of 72
2 open now
Registered
27th of 72
by date
Lead sponsor
2 of 72
Bio-Thera Solutions

Among the 72 studies in Macular Edema with a site in China, this one is the 47th largest by enrollment of the 65 interventional ones that give a count, is one of 5 that started in 2020, is one of 7 in phase 1/2, and was the 27th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

18 of the 72 studies in Macular Edema with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Macular Edema with a site in China, or all of them as a file.
02

Study summary

This study is a multi-center, open, multiple-dose phase Ib/IIa clinical study evaluating the efficacy and safety of BAT5906 injection in patients with diabetic macular edema. BAT5906's phase I study on w-AMD shows that it is safe from 0.3-4.0 mg, and the higher dose (2.5 mg and 4 mg) may maintain the anti-VEGF effect for a longer time just like the same target drugs (such as brolucizumab and Abecip ) It has also been found in clinical studies that high doses can extend the dosing interval and reduce the dosing frequency. Therefore, in this study, two safe and effective doses were selected, and the optimal clinical effective dose and frequency of BAT5906 in DME were initially explored.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • DME
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Only the following criteria are met:

    1. Sign the voluntarily, willing and capable to follow the procedures of outpatient visits and research at the time specified in the trial
    2. Diagnosed with type 1 or type 2 diabetes, aged 18 to 80 years old;
    3. The drug treatment to control diabetes must be stable within 3 months before randomization and is expected to remain stable during the study period;
    4. Macular edema secondary to diabetes, and found to be involved in the macular center (fovea) of the research eye by OCT examination, confirmed by the reading center during screening;
    5. The study eye is assessed by OCT with CRT ≥ 250 µm;
    6. BCVA in the study eye is 73 to 21 letters (using the ETDRS chart, inclusive of boundary values, equivalent to a Snellen visual acuity score of 20/40 to 20/400 in the study eye).
    7. BCVA in the fellow eye is ≥24 letters (using the ETDRS chart, equivalent to Snellen visual acuity ≥20/320). Note: If both eyes meet the inclusion criteria, the eye with the worse baseline visual acuity will be selected as the study eye.
    8. At the time of screening and baseline, the investigator judged that the contralateral eye was expected to not require any anti-VEGF treatment within 3 months (PK group only).

Exclusion criteria

Exclusion Criteria:

  • If a patient meets any of the following conditions, they cannot enter the study:

Eye exclusion criteria:

  1. There is structural damage to the center of the macula in the eye, and the best corrected vision may not be improved after the macular edema resolves, including atrophy of retinal pigment epithelial cells, subretinal fibrosis or scarring, and obvious macular ischemia (FFA suggests arching Obvious damage), macular anterior membrane involving fovea or organic hard exudate (as confirmed by the reading center before randomization);
  2. The research eye has iris lesions and neovascular glaucoma;
  3. Those who have no eye lens (except intraocular lens);
  4. The study eye has active hyperplastic diabetic retinopathy (PDR);
  5. The research eye has anyone other than diabetic macular edema that may confuse macular assessment or vision testing (retinal vascular occlusion, retinal detachment, vitreous macular traction, macular hole, preretinal fibrosis involving the macula, choroidal neovascularization, age Related macular degeneration, etc.);
  6. The research eye is accompanied by poorly controlled glaucoma, which is defined as the intraocular pressure still ≥21mmHg after treatment with anti-glaucoma drugs, or according to the judgment of the investigator;
  7. The research eye has undergone or may have undergone anti-glaucoma surgery during the study period (including trabeculectomy, sclerectomy and non-penetrating trabecular surgery, etc.);
  8. The research eye has undergone vitreoretinal surgery or scleral buckling;
  9. At the time of screening and baseline, the study eye had received laser photocoagulation (total retina or macular laser photocoagulation) within 90 days (including 90 days) or during the study period;
  10. At the time of screening and baseline, the study eye had any intraocular or perocular surgery within 90 days (including 90 days) (except for yttrium-aluminum-garnet (YAG) lens capsule incision and eyelid surgery for more than 30 days) ;
  11. A history of uveitis in any eye;
  12. Any eye has active ocular inflammation or infection (bacterial, viral, parasitic or fungal infection);
  13. At the time of screening and baseline, any eye had received intraocular anti-VEGF treatment within the first 90 days (including 90 days), such as ranibizumab, bevacizumab, abercept, compacept, etc.;
  14. At the time of screening and baseline, any eye has received intraocular, periocular, and subconjunctival treatment within the first 90 days (including 90 days);

    Exclusion criteria for abnormal conditions in laboratory inspection:

  15. Abnormal liver and kidney function (this test specifies that and AST should not be higher than the value of the laboratory in the center by 2.5 times; Crea and BUN should not be higher than the upper limit of the normal value of the laboratory in the center by 2 times);
  16. Abnormal blood coagulation function ( ≥ upper limit of normal value 3 seconds, activated partial thromboplastin time ≥ upper limit of normal value 10 seconds);
  17. Any one of the infected patients: active (if HBsAg(+) requires HBV DNA must be> 500 IU/mL or the hospital maximum limit), , AIDS or syphilis (positive RPR test);

    Other exclusion criteria:

  18. Myocardial infarction or stroke occurred within 6 months before the first dose;
  19. Poorly controlled diabetes mellitus [defined as glycosylated () > 10%];
  20. Accompanied by uncontrollable hypertension (defined as blood pressure >150/100 mmHg after treatment with antihypertensive drugs);
  21. Patients who took large doses of oral or injectable corticosteroids and other hormonal drugs (>10 mg prednisolone or the same dose/day) within 6 months before screening, but patients who used steroid drugs for inhalation, nasal cavity or local skin small doses except;
  22. Those who have undergone surgery within 1 month and have not healed, or according to the investigator's judgment;
  23. There is a history of to the study drug, metabolic dysfunction, physical examination results, or a disease or symptom that is reasonably suspected of being based on clinical laboratory results is a contraindication to the study drug, which may affect the judgment of the study results, or make the subject suffer Higher risk of complications;
  24. Allergy or contraindications to known research drugs or their ingredients, fluorescein or povidone iodine;
  25. Those who participated in clinical trials of any drugs (except vitamins and minerals) or devices 90 days before the first dose (including 90 days);
  26. Women who are pregnant, pregnant or breastfeeding (pregnancy is defined as a positive blood/urine pregnancy test in this trial); male or female subjects of fertility do not agree to the entire study period and within 3 months after the end of the visit period Take appropriate measures (such as IUD, birth control pills or condoms, etc.). For women who have not been menopausal or have been menopausal but have not met the menopause time continuously for more than 12 months, and have not undergone sterilization surgery (ovarian and/or hysterectomy), they are defined as having fertility. The definition of fertility may be adjusted according to local standards in each region.

    Note: High-efficiency contraception methods include total abstinence, IUD, double barrier method (eg condom + diaphragm with spermicides, implanted contraceptives, hormonal contraceptives [contraceptives, implanted contraceptives, transdermal Patches, hormone-vaginal devices or sustained-release injections], or the partner has undergone a vasectomy and is confirmed to have no sperm);

  27. The researchers believe that there are other conditions that need to be excluded.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    2.5mg of BAT5906

    Specification: 10 mg/0.2 mL per vial Route of Administration: Intravitreal Injection Dose: 2.5 mg per eye per administration (50 μL) Treatment Regimen: One injection every 4 weeks for 6 consecutive administrations; follow-up visits will be conducted every 4 weeks thereafter, with PRN retreatment permitted at the investigator's discretion, and subjects will be followed up until Week 48.

    Drug: 2.5mg of BAT5906

  • Experimental
    4mg of BAT5906

    Specification: 16 mg/0.2 mL per vial; Route of Administration: Intravitreal Injection; Dose: 4 mg per eye per administration (50 μL); Treatment Regimen: One injection every 4 weeks for 3 consecutive administrations; follow-up visits will be conducted every 4 weeks thereafter, with PRN retreatment permitted at the investigator's discretion, and subjects will be followed up until Week 48.

    Drug: 4.0mg of BAT5906

Interventions

  • Drug2.5mg of BAT5906

    Specification: 2.5mg of BAT5906

  • Drug4.0mg of BAT5906

    Specification: 4.0mg of BAT5906

06

What researchers measure

Primary outcomes

  1. 1.1 Safety evaluation - Vital signs# the patient's body temperature;

    the patient's body temperature (axillary temperature) Any clinically significant abnormality should be reported as an adverse event and recorded in the original

    Time frame: Day-14~Day-1;Day0;Day28;Day56;Day84;Day112;Day140;Day168;Day196;Day224;Day252;Day280;Day308;Day336

  2. 1.2 Safety evaluation - Vital signs# heart rate/pulse

    heart rate/pulse Any clinically significant abnormality should be reported as an adverse event and recorded in the original

    Time frame: Day-14~Day-1;Day0;Day28;Day56;Day84;Day112;Day140;Day168;Day196;Day224;Day252;Day280;Day308;Day336

  3. 1.3 Safety evaluation - Vital signs# respiratory rate

    respiratory rate Any clinically significant abnormality should be reported as an adverse event and recorded in the original

    Time frame: Day-14~Day-1;Day0;Day28;Day56;Day84;Day112;Day140;Day168;Day196;Day224;Day252;Day280;Day308;Day336

  4. 1.4 Safety evaluation - Vital signs# blood pressure

    blood pressure Any clinically significant abnormality should be reported as an adverse event and recorded in the original

    Time frame: Day-14~Day-1;Day0;Day28;Day56;Day84;Day112;Day140;Day168;Day196;Day224;Day252;Day280;Day308;Day336

  5. Number of subjects with clinically significant abnormal physical examination signs identified byprotocol-specified full physical examination (general appearance, skin, lungs, heart, abdomen,extremities, musculoskeletal system)

    Full physical examination including general appearance, skin, pulmonary, cardiac, abdominalextremity and musculoskeletal assessments will be performed per study evaluation schedule. Allclinically significant abnormalities relative to baseline screening physical exam findings will bedocumented as adverse events. The primary summary metric is the proportion and number ofsubjects presenting 21 clinically significant abnormal physical examination finding during on-treatment study visits.

    Time frame: Day-14~Day-1;Day84;Day168;Day336

  6. Number of participants with clinically significant abnormal laboratory findings

    Laboratory examinations include complete blood count, urinalysis, blood biochemistry (including liver and renal function), and coagulation function. Clinically significant changes from baseline will be assessed and reported as adverse events (AEs) based on CTCAE v4.0 criteria.

    Time frame: Day-14~Day-1;Day84;Day168;Day336

  7. Number of participants with clinically significant abnormal ECG findings

    The 12-lead ECG will be performed to measure parameters including heart rate, PR interval, QRS duration, and QT/QTc interval. Clinically significant changes from baseline will be assessed by the investigator and recorded as adverse events

    Time frame: Day-14~Day-1;Day84;Day168;Day336

  8. Anti-drug antibody (ADA);

    Plasma samples for anti-drug antibody (ADA) detection were collected to detect the positive incidence of ADA associated with plasma levels of BAT5906

    Time frame: Screening (within 24 hours prior to first dose), Day 7 (168h), Day 14 (336h), prior to the 3rd dose (within 24 hours), and prior to the 5th dose through end of study visit (as needed)

  9. ocular and non-ocular adverse events (AE) and serious adverse events (SAE)

    Any adverse medical event that occurs after a subject participates in a clinical trial and receives the investigational drug, but is not necessarily cause-and-effect with the treatment. An adverse event can be any adverse or unexpected sign (including abnormal laboratory tests), symptom, or disease, whether or not it is drug related.

    Time frame: Adverse events were collected from the time the patient signed the informed consent to the time 28 days after the last dication

  10. Efficacy evaluation

    2.1 Primary efficacy endpoint (study eye):Change from baseline in BCVA

    Time frame: at Week 36

  11. Pharmacokinetic (PK) Evaluation

    Blood samples were collected from each treatment group throughout the study to determine the serum concentration of BAT5906 Injection. The PK blood sample collection schedule is detailed in the PK/VEGF/ADA Blood Collection Schedule.

    Time frame: Once within 24 hours before administration.6 hours after administration, 24 hours after administration(once every 3 days) up to 672 hours after administration

  12. Peripheral Blood VEGF Assessment (VEGF)

    lood samples were collected from each treatment group throughout the study to measure blood VEGF concentrations. The blood sample collection schedule is detailed in the PK/VEGF/ADA Blood Sampling Schedule

    Time frame: Once within 24 hours before administration.24 hours after administration (once every 7 days) up to 672hours after administration

  13. Immunogenicity Assessment

    Anti-BAT5906 antibodies (ADA) were detected. The blood sample collection schedule is detailed in the PK/VEGF/ADA Blood Sampling Schedule. Anti-drug antibodies (ADA) in serum were detected; samples confirmed positive for ADA were subsequently analyzed for neutralizing antibodies (Nab)

    Time frame: First administration: within 24 hours prior to administration.168 hours and 336 hours after administration,and the second until the last administration: within 24 hours before administration

Secondary outcomes

  1. 1、Efficacy evaluation

    1.1 Change from baseline in BCVA 1.2 Change from baseline in CRT as assessed by OCT 1.3 Proportion of subjects with a ≥10-letter gain from baseline in BCVA, a ≥15-letter gain from baseline in BCVA, and a ≥15-letter loss from baseline in BCVA 1.4 Mean number of BAT5906 injections administered

    Time frame: at Weeks 12, 24, and 48

07

Study locations

19 sites
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijiang, Beijing Municipality 100730, China
  • Eye Hospital of China Academy of Chinese Medical Sciences
    Beijing, China
  • Peking University First Hospital
    Beijing, China
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, China
  • Henan Provincial Eye Hospital
    Henan, China
  • Jieyang People's Hospital
    Jieyang, China
  • The First Hospital of Jilin University
    Jilin City, China
  • The Affiliated Eye Hospital of Nanchang University
    Nanchang, China
  • Jiangsu Provincial Hospital of Traditional Chinese Medicine
    Nanjing, China
  • Affiliated Hospital of Nantong University
    Nantong, China
  • Affiliated Hospital of Qingdao University
    Qingdao, China
  • Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong
    Shantou, China
  • West China Hospital of Sichuan University
    Sichuan, China
  • Wenzhou Medical University Affiliated Optometry Hospital
    Wenzhou, China
  • The Second Xiangya Hospital of Central South University
    Xiangya, China
  • Xiangya Hospital Central South University
    Xiangya, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Nov 2023, 36 months.

Of 16 phase 1/2 interventional studies under Macular Edema, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 68. This study's 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2020
First posted
Feb 26, 2021
StartActual
Oct 16, 2020
Primary completionActual
Nov 6, 2023
CompletionActual
Nov 6, 2023
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04772105
Responsible party
Sponsor
First posted
Feb 26, 2021
Start date
Oct 16, 2020
Primary completion
Nov 6, 2023
Completion
Nov 6, 2023
Last update
Jul 14, 2026

Study contacts

Youxin Chen
principal investigator · Peking Union Medical College

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion